Location History:
- Thief River Falls, MN (US) (2002)
- White Plains, NY (US) (2014)
- Los Angeles, CA (US) (2022)
Company Filing History:
1 out of 224 
1 out of 1,537 
2 out of 832,880 Years Active: 2002-2022
Title: David Charles Thompson: Innovator in Cathepsin-S Inhibitors
Introduction
David Charles Thompson is an accomplished inventor based in White Plains, NY, known for his significant contributions to the field of pharmaceuticals. His focus on developing innovative compounds has led to advancements in treatments for autoimmune diseases.
Latest Patents
Thompson holds a patent for "Heteroaryl nitrile compounds useful as inhibitors of Cathepsin-S." This intriguing patent discloses reversible inhibitor compounds that can play a crucial role in the treatment of autoimmune and other diseases. Additionally, it outlines pharmaceutical compositions that incorporate these compounds, including methods for their production and application in therapeutic settings.
Career Highlights
Currently, David Thompson is an integral member of Boehringer Ingelheim International GmbH, a leading global pharmaceutical company. His work there emphasizes innovation in drug discovery, focusing on improving patient outcomes through effective pharmaceutical solutions.
Collaborations
During his career, Thompson has collaborated with fellow innovators, including Michael Jason Burke and Derek Cogan. Their joint efforts have contributed to the advancement of therapeutic strategies and the development of novel pharmaceutical applications.
Conclusion
David Charles Thompson exemplifies the spirit of innovation in the pharmaceutical industry. Through his patented research on Cathepsin-S inhibitors and his collaborative endeavors at Boehringer Ingelheim International GmbH, he continues to impact the treatment landscape for autoimmune diseases and beyond.